Multicenter Study

. 2025 Jul;48(7):739-752.

doi: 10.1007/s40264-025-01526-9. Epub 2025 Mar 15.

QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ

Mona Gerentes^{1

2}, Mohamed Lajnef^{1

2}, Andrei Szöke^{1

2}, Bruno Aouizerate^{1

3

4}, Fabrice Berna^{1

5}, Maud Cléry^{1

2}, Isabelle Chéreau^{1

6}, Nathalie Coulon^{1

7}, Julia Clauss-Kobayashi^{1

5}, Eric Fakra^{1

8}, Jean-Michel Dorey^{1

9

10}, Caroline Dubertret^{1

11

12

13}, Guillaume Fond^{1

14}, Ophélia Godin^{1

2}, Tudi Goze^{1

15}, Christophe Lançon^{1

14}, Marion Leboyer^{1

2}, Sylvain Leignier^{1

7}, Pierre-Michel Llorca^{1

6}, Jasmina Mallet^{1

11

12

13

16}, David Misdrahi^{1

3

4}, Nicolas Oriol^{1

8}, Romain Rey^{1

9

10}, Paul Roux^{1

17}, Benoit Schorr¹⁵, Mathieu Urbach^{1

17}, Etienne Véry^{1

18}; FACE-SZ (FondaMental Academic Centers of Expertise-Schizophrenia) Group; Franck Schürhoff^{1

2}, Baptiste Pignon^{19

20

21}

Collaborators, Affiliations

Collaborators

FACE-SZ (FondaMental Academic Centers of Expertise-Schizophrenia) Group:
M Andre, C Andrieu-Haller, B Aouizerate, F Berna, O Blanc, D Capdevielle, M Cléry, I Chereau-Boudet, J Clauss-Kobayashi, N Coulon, R Dassing, J M Dorey, C Dubertret, A Esselin, G Fond, F Gabayet, M Jarroir, D Lacelle, M Leboyer, S Leignier, P M Llorca, J Mallet, E Metairie, T Michel, D Misdrahi, C Passerieux, B Pignon, P Peri, C Portalier, R Rey, C Roman, B Schorr, F Schürhoff, A Szöke, A Tessier, M Urbach, A Zinetti-Bertschy

Affiliations

¹ FondaMental Foundation, 94010, Créteil, France.
² Univ Paris-Est-Créteil (UPEC), AP-HP, Hôpitaux Universitaires "H. Mondor", DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Créteil, France.
³ General and University Psychiatry Department, Charles Perrens Hospital, 33076, Bordeaux, France.
⁴ Univ. Bordeaux, CNRS, INCIA, UMR 5287, 33000, Bordeaux, France.
⁵ Department of Psychiatry, University Hospitals of Strasbourg, University of Strasbourg, Inserm U1114, Strasbourg, France.
⁶ CHU Clermont-Ferrand, Service of Psychiatry B, University of Clermont Auvergne, Clermont-Ferrand, France.
⁷ Grenoble Alpes University, Inserm U1216, CHU Grenoble Alpes, Grenoble Institute of Neurosciences, Grenoble, France.
⁸ Department of Psychiatry, University Hospital of Saint-Etienne, Saint-Etienne, France.
⁹ Le Vinatier Hospital, Schizophrenia Expert Centre, 69500, Bron, France.
¹⁰ INSERM, U1028, CNRS, UMR5292, University Lyon 1, Lyon Neuroscience Research Center, PSYR2 Team, 69000, Lyon, France.
¹¹ AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France.
¹² Inserm UMR1266, Institute of Psychiatry and Neuroscience of Paris, University Paris Descartes, Paris, France.
¹³ Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, Paris, France.
¹⁴ APHM, Service de psychiatrie universitaire, Aix-Marseille université, Marseille, France.
¹⁵ Department of Psychiatry, Psychotherapies, Art-therapy, Toulouse University HospitalEquipe de Recherche sur les Rationalités Philosophiques et les Savoirs-EA3051, Université de Toulouse-Jean Jaurès, Toulouse, France.
¹⁶ Department of Psychiatry, Centre Hospitalier Universitaire d'Orléans, EPSM du Loiret, University of Orléans, Centre Hospitalier Universitaire d'Orléans, Orléans, France.
¹⁷ Versailles Hospital, Department of Adult Psychiatry and Addictology, Centre Hospitalier de Versailles, Service universitaire de psychiatrie d'adultes et d'addictologie, Le Chesnay, Université Paris-Saclay, Université de Versailles Saint-Quentin-En-Yvelines, DisAP-DevPsy-CESP, INSERM UMR1018, Villejuif, France.
¹⁸ Department of Psychiatry, Psychotherapies, Art-therapy, Toulouse University Hospital, ToNIC, Toulouse Neuroimaging Center, INSERM UMR 1214, Toulouse, France.
¹⁹ FondaMental Foundation, 94010, Créteil, France. baptistepignon@yahoo.fr.
²⁰ Univ Paris-Est-Créteil (UPEC), AP-HP, Hôpitaux Universitaires "H. Mondor", DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Créteil, France. baptistepignon@yahoo.fr.
²¹ Hôpital Albert Chenevier, Groupe hospitalier Henri-Mondor, CHU de Créteil, Assistance Publique-Hôpitaux de Paris (AP-HP), 40 rue de Mesly, 94000, Créteil, France. baptistepignon@yahoo.fr.

PMID: 40088341
DOI: 10.1007/s40264-025-01526-9

Multicenter Study

QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ

Mona Gerentes et al. Drug Saf. 2025 Jul.

. 2025 Jul;48(7):739-752.

doi: 10.1007/s40264-025-01526-9. Epub 2025 Mar 15.

Authors

Collaborators

FACE-SZ (FondaMental Academic Centers of Expertise-Schizophrenia) Group:
M Andre, C Andrieu-Haller, B Aouizerate, F Berna, O Blanc, D Capdevielle, M Cléry, I Chereau-Boudet, J Clauss-Kobayashi, N Coulon, R Dassing, J M Dorey, C Dubertret, A Esselin, G Fond, F Gabayet, M Jarroir, D Lacelle, M Leboyer, S Leignier, P M Llorca, J Mallet, E Metairie, T Michel, D Misdrahi, C Passerieux, B Pignon, P Peri, C Portalier, R Rey, C Roman, B Schorr, F Schürhoff, A Szöke, A Tessier, M Urbach, A Zinetti-Bertschy

Affiliations

¹ FondaMental Foundation, 94010, Créteil, France.
² Univ Paris-Est-Créteil (UPEC), AP-HP, Hôpitaux Universitaires "H. Mondor", DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Créteil, France.
³ General and University Psychiatry Department, Charles Perrens Hospital, 33076, Bordeaux, France.
⁴ Univ. Bordeaux, CNRS, INCIA, UMR 5287, 33000, Bordeaux, France.
⁵ Department of Psychiatry, University Hospitals of Strasbourg, University of Strasbourg, Inserm U1114, Strasbourg, France.
⁶ CHU Clermont-Ferrand, Service of Psychiatry B, University of Clermont Auvergne, Clermont-Ferrand, France.
⁷ Grenoble Alpes University, Inserm U1216, CHU Grenoble Alpes, Grenoble Institute of Neurosciences, Grenoble, France.
⁸ Department of Psychiatry, University Hospital of Saint-Etienne, Saint-Etienne, France.
⁹ Le Vinatier Hospital, Schizophrenia Expert Centre, 69500, Bron, France.
¹⁰ INSERM, U1028, CNRS, UMR5292, University Lyon 1, Lyon Neuroscience Research Center, PSYR2 Team, 69000, Lyon, France.
¹¹ AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France.
¹² Inserm UMR1266, Institute of Psychiatry and Neuroscience of Paris, University Paris Descartes, Paris, France.
¹³ Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, Paris, France.
¹⁴ APHM, Service de psychiatrie universitaire, Aix-Marseille université, Marseille, France.
¹⁵ Department of Psychiatry, Psychotherapies, Art-therapy, Toulouse University HospitalEquipe de Recherche sur les Rationalités Philosophiques et les Savoirs-EA3051, Université de Toulouse-Jean Jaurès, Toulouse, France.
¹⁶ Department of Psychiatry, Centre Hospitalier Universitaire d'Orléans, EPSM du Loiret, University of Orléans, Centre Hospitalier Universitaire d'Orléans, Orléans, France.
¹⁷ Versailles Hospital, Department of Adult Psychiatry and Addictology, Centre Hospitalier de Versailles, Service universitaire de psychiatrie d'adultes et d'addictologie, Le Chesnay, Université Paris-Saclay, Université de Versailles Saint-Quentin-En-Yvelines, DisAP-DevPsy-CESP, INSERM UMR1018, Villejuif, France.
¹⁸ Department of Psychiatry, Psychotherapies, Art-therapy, Toulouse University Hospital, ToNIC, Toulouse Neuroimaging Center, INSERM UMR 1214, Toulouse, France.
¹⁹ FondaMental Foundation, 94010, Créteil, France. baptistepignon@yahoo.fr.
²⁰ Univ Paris-Est-Créteil (UPEC), AP-HP, Hôpitaux Universitaires "H. Mondor", DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Créteil, France. baptistepignon@yahoo.fr.
²¹ Hôpital Albert Chenevier, Groupe hospitalier Henri-Mondor, CHU de Créteil, Assistance Publique-Hôpitaux de Paris (AP-HP), 40 rue de Mesly, 94000, Créteil, France. baptistepignon@yahoo.fr.

PMID: 40088341
DOI: 10.1007/s40264-025-01526-9

Abstract

Background: The life expectancy of patients with schizophrenia is reduced, partly due to cardiovascular diseases. Antipsychotics are associated with QT interval prolongation, which is a risk factor for arrhythmia and cardiac arrest. The differences between antipsychotic with regard to QT interval prolongation are not well understood.

Objective: The aim was to compare the QT values associated with different antipsychotics within a real-world population of subjects with clinically stable forms of schizophrenia.

Methods: The FACE-SZ cohort comprises subjects with psychotic disorders, referred to schizophrenia expert cents. QT interval was measured, as well as all treatments (psychotropic and others). The following maintenance treatment for schizophrenia was analysed cross-sectionally: aripiprazole, clozapine, haloperidol, amisulpride, olanzapine, quetiapine, risperidone. Age, sex, smoking status, body mass index, blood potassium levels, and the co-prescription of another QT-prolonging treatment were used as adjustment factors in multivariable linear regression analyses.

Results: Among 792 patients, the mean corrected QT (QTc) interval in the sample of patients under monotherapy was 407 ms. The mean age was 31.7 years, and the majority were male (73.3 %). In comparison to the rest of the sample, clozapine was associated with a longer QTc interval (β = 0.012, 95% CI [0.006-0.018]), while aripiprazole was significantly associated with a shorter QTc interval (β = - 0.010, 95% CI [- 0.016 to - 0.005]). Other antipsychotics were not associated with significant variations of the QTc.

Conclusions: The prescription of antipsychotics should always be accompanied by close monitoring of the QTc interval to prevent the risk of severe cardiac arrhythmia, particularly concerning clozapine.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: This work was supported by the “Investissements d'Avenir” programmes managed by the ANR under references ANR-11-IDEX-0004-02 and ANR-10-COHO-10-01. The funding source had no further involvement in study design; the collection, analysis and interpretation of data; the writing of the report or in the decision to submit the article for publication. Conflicts of interest: The Authors have declared that there are no conflicts of interest in relation to the subject of this study. Availability of data and materials: Data are not available. Code availability: The code is not available. Author contributions: MG, MoLa, FS and BP devised the study design. Data collection was conducted by the FACE-SZ collaborators. MG and MoLa conducted data analysis, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MG and BP wrote the first draft of the manuscript. MG, AS, BA, FB, MC, IS, NC, JCK, EF, JMD, CD, GF, OG, TG, CL, MaLe, SL, PML, JM, DM, NO, RR, PR, BS, MU, EV, FS and BP participated in interpreting the results, manuscript editing and figure revision. All authors approved the final version of the manuscript. Ethics approval: The assessment protocol was approved by the ethics review board (CPP-Ile de France IX, January 18, 2010), which required providing all patients with an informational letter but waived the requirement for written informed consent. Consent to participate: This study was conducted using data collected from Expert Centres as part of regular care evaluations. The research is classified as observational and non-interventional. It received a favourable opinion from the French Advisory Committee on Information Processing for Health Research (CCTIRS) and authorization from the French National Commission on Informatics and Liberty (CNIL). Patients were informed through an information letter, and a non-opposition form was provided to them for the collection and use of their data for research purposes. Consent for publication: Patients were informed through an information letter, and a non-opposition form was provided for the collection and use of their data for research purposes.

References

1. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. AJP. 2013;170:324–33. - DOI
1. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211:175–81. - PubMed - PMC - DOI
1. Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47:1549–56. - PubMed - DOI
1. Kowal C, Peyre H, Amad A, Pelissolo A, Leboyer M, Schürhoff F, et al. Psychotic, mood, and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis. Psychosom Med. 2020;82:838–49. - PubMed - DOI
1. Veeneman RR, Vermeulen JM, Abdellaoui A, Sanderson E, Wootton RE, Tadros R, et al. Exploring the relationship between schizophrenia and cardiovascular disease: a genetic correlation and multivariable mendelian randomization study. Schizophr Bull. 2022;48:463–73. - PubMed - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ

Collaborators

Affiliations

QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical